Department of Pharmacology, Fr. Muller Medical College, Mangalore - 575 002, India.
Indian J Psychiatry. 2011 Jan;53(1):25-9. doi: 10.4103/0019-5545.75557.
Assessment of safety and efficacy profile of disulfiram (DSM) in the alcoholic de-addiction regimen.
a. Assessment of Adverse Drug Reaction (ADR) profile; b. Evaluation of effectiveness of various deaddiction regimen; c. Defaulters and dropouts
Fifty-one patients in a de-addiction center were investigated on 0(th) , 30(th) and 60(th) day along with psychiatric evaluation, ADR surveillance was made. Statistical analysis was done thereafter.
125 mg DSM given OD for 2 months. 76.5% patients had taken full course of treatment, 45% didn't complain of any ADR. Of ADR reported 27.4% had drowsiness, 21.4% tiredness, 7.8% skin manifestation.
DSM is the main drug among naltrexone, acamprosate, nalmefene and other drugs used in alcoholic de-addiction. Relative and effectiveness is lost by the degree of dropouts and hence relapses. Low-dose DSM had decreased adverse effects with 76.5% patients taking the full course of treatment. DSM alters liver functions as there were significant changes in the lab parameters of SGPT(P=0.007), SGOT(P=0.001), GGT(P=<0.001) between first and third samples. Occurrence of ADR is not the cause of default; patients find it confusing to differentiate between the symptoms of alcohol withdrawal and those due to ADR of DSM.
评估双硫仑（DSM）在酒精戒毒方案中的安全性和疗效概况。
a. 评估药物不良反应（ADR）概况；b. 评估各种戒毒方案的有效性；c. 违约者和辍学率。
在戒毒中心对 51 名患者进行了调查，分别在第 0、30 和 60 天进行了精神病学评估和 ADR 监测。随后进行了统计分析。
给予 DSM 125mg ，每天一次，连续 2 个月。76.5%的患者完成了全程治疗，45%的患者没有报告任何不良反应。报告的不良反应中，27.4%有嗜睡，21.4%疲倦，7.8%皮肤表现。
DSM 是纳曲酮、安非他酮、纳美芬和其他用于酒精戒毒药物中的主要药物。由于辍学率和复发率的原因，相对和有效性会降低。低剂量的 DSM 减少了不良反应，76.5%的患者完成了全程治疗。DSM 改变了肝功能，因为 SGPT（P=0.007）、SGOT（P=0.001）和 GGT（P=<0.001）的实验室参数在第一和第三样本之间有显著变化。不良反应的发生不是违约的原因；患者发现难以区分酒精戒断症状和 DSM 不良反应的症状。
